Synopsis: Predicting overall survival in HCC patients before initiating treatment is essential to personalize a treatment plan for each patient. Barcelona clinic liver cancer (BCLC) is one of the current criteria for predicting pre-therapeutic overall survival (OS). Several studies suggested a valuable role of functional MRI biomarkers including diffusion-weighted imaging (DWI) with apparent diffusion coefficients (ADC), tumor venous enhancement (VE) and tumor volume (TV) in tumor response assessment. These metrics rely on changes post therapy; none of these parameters assessed baseline values of these variables in predicting OS before starting treatment.
This abstract and the presentation materials are available to members only; a login is required.